Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial by Macarulla Mercadé, Teresa et al.
Journal of Geriatric Oncology 10 (2019) 427–435
Contents lists available at ScienceDirect
Journal of Geriatric OncologyLiposomal irinotecan and 5-fluorouracil/leucovorin in older patientswith
metastatic pancreatic cancer – A subgroup analysis of the pivotal
NAPOLI-1 trialTeresa Macarulla a,⁎, Jean-Frédéric Blanc b, Andrea Wang-Gillam c, Li-Tzong Chen d,e, Jens T. Siveke f,g,
Beloo Mirakhur h, Jie Chen i, Floris A. de Jong j
a Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
b Pôle ADEN, Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France
c Division of Oncology, Washington University in St. Louis, MO, USA
d National Institute of Cancer Research, National Health Research Institutes, National Cheng Kung University, Tainan, Taiwan
e Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan
f Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany
g Cancer Consortium (DKTK, partner site Essen), German Cancer Research Center, DKFZ, Heidelberg, Germany
h Ipsen Biopharmaceuticals, Inc., Cambridge, MA, United States
i Shire plc, Cambridge, MA, United States
j Global Medical Affairs, Servier, Zurich, Switzerland⁎ Corresponding author at: Medical Oncology Dep
Endocrine Tumor Unit, Vall d'Hebron University Hos
Institute of Oncology (VHIO), Paseo Vall Hebrón 119-129,
E-mail address: tmacarulla@vhebron.net (T. Macarulla
https://doi.org/10.1016/j.jgo.2019.02.011
1879-4068/© 2019 The Authors. Published by Elsevier Ltda b s t r a c ta r t i c l e i n f oArticle history:
Received 31 August 2018
Received in revised form 20 November 2018
Accepted 19 February 2019
Available online 4 March 2019Objectives: Pancreatic cancer is a highly lethal disease predominantly affecting older patients. Characterization of
outcomes in these patients may help optimise treatment decisions. The global, phase 3 NAPOLI-1 trial
(NCT01494506) demonstrated an overall survival (OS) benefit with liposomal irinotecan and 5-flurouracil/
leucovorin (nal-IRI + 5-FU/LV) versus 5-FU/LV. This subgroup analysis explored impact of age on outcomes in
NAPOLI-1 patients, and nal-IRI + 5-FU/LV efficacy and safety in older patients.
Materials andMethods: This exploratory, post-hoc analysis of the NAPOLI-1 trial included patients aged ≥eighteen
years (no upper limit) with metastatic pancreatic adenocarcinoma that had progressed on gemcitabine-based
therapy. Patients were stratified by age (cut-offs at 65, 70, and 75 years); OS and progression-free survival
(PFS) were estimated by Kaplan-Meier analysis.
Results: Of 417 randomized patients, 192 (46%), 110 (26%) and 43 (10%) were aged ≥65, ≥70 and ≥ 75 years,
respectively. Mortality risk and risk of disease progression were similar in older and younger patients indepen-
dent of treatment (HRs for median [m]OS/mPFS comparisons were 0.88/0.95 [b65 versus ≥65 years], 0.89/0.88
[b70 versus ≥70 years] and 1.04/0.98 [b75 versus ≥75 years]; P N .25). Reduced mortality/morbidity risk with
nal-IRI + 5-FU/LV in older subgroups was in line with the wider population. No additional toxicities with nal-
IRI + 5-FU/LV were observed in older patients: 86% of patients ≥75 years versus 69% b75 years required a dose
delay or reduction due to toxicities (43% versus 32% dose reductions).
Discussion: Results suggest that older patients with metastatic pancreatic adenocarcinoma that progressed on
prior gemcitabine-based treatment can benefit from second-line therapy, supporting nal-IRI + 5-FU/LV treat-
ment in older patients.
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. This is an open access article under1. Introduction
Pancreatic cancer predominantly affects older patients – themedian
age at diagnosis is 70 years, and approximately two-thirds of cases are
in patients older than 65 years [1,2]. Mortality closelymirrors incidence
[3], with almost 70% of related deaths occurring in patients over
65 years old [1,2]. The incidence and mortality of pancreatic cancer
has increased alongside a demographic shift towards an agingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
428 T. Macarulla et al. / Journal of Geriatric Oncology 10 (2019) 427–435population [3,4]. Meanwhile, five-year survival rates remain in single
digits [3,5,6], particularly in older patients (5.8% in the 65–79 age
group and 3.3% in patients aged ≥80 years) [7]. Without significant ad-
vances in early detection strategies and effective treatments, pancreatic
cancer is projected to become the second greatest cause of cancer-
related death in the US by 2030 [5].
Despite the predominance of pancreatic cancer in older patients,
they are often under-represented in, or excluded from, clinical trials
[8–11], and a smaller proportion receive chemotherapy, or other
tumour-targeted treatment, in clinical practice compared with younger
patients [8,9,12]. Treatment bias towards higher rates of intervention
for younger patients has also been observed with surgical resection
[13]. Although treatment guidelines state that advanced age is not in it-
self a contraindication for any major treatment modality (surgery, che-
motherapy or radiation) [14], physicians must take account of frailty
and comorbidity when determining appropriate treatment. Despite
perceptions that older patients are likely to have worse outcomes, sev-
eral studies have observed similar benefit in younger and older patients
undergoing chemotherapy [8,9], surgical resection [13,15,16], or any
tumour-targeted treatment [12].
Gemcitabine-based therapy is often the preferred first-line chemo-
therapy option for older patientswithmetastatic pancreatic adenocarci-
noma because it is generally well tolerated. More intensive regimens,
such as FOLFIRINOX or gemcitabine plus nab-paclitaxel, have demon-
strated superior efficacy to gemcitabine monotherapy [10,17], but
with increased toxicity, therefore these regimens are recommended
for patients with good performance status (Eastern Cooperative Oncol-
ogy Group 0–1) [14,18,19], who tend to be younger and fitter. Indeed,
patients aged 75 and over were excluded from the pivotal PRODIGE 4/
ACCORD 11 trial of FOLFIRINOX [10].
Liposomal irinotecan (nal-IRI) in combinationwith 5-flurouracil and
leucovorin (5-FU and LV)was thefirst regimen to be approved for use as
second-line therapy for metastatic pancreatic adenocarcinoma, based
on results of the pivotal NAPOLI-1 trial [20,21]. NAPOLI-1 was a global,
phase 3 study of nal-IRI, as monotherapy and in combination with 5-
FU/LV, in patients with metastatic pancreatic adenocarcinoma who
had progressed following gemcitabine-based therapy [22]. Overall sur-
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Fig. 1. Patient flow in the phase 3 NAPOLI-1 trial split by age group to highlight the efficacy p
adenocarcinoma and had previously progressed on gemcitabine-based treatment. The CONSORimproved with nal-IRI + 5-FU/LV versus the 5-FU/LV control and qual-
ity of life was maintained over time; adverse events were predictable
and manageable.
A pre-specified subgroup analysis of the NAPOLI-1 study indicated
that improvements in OS with nal-IRI + 5-FU/LV versus 5-FU/LV alone
were similar in patients aged ≤65 and N 65 years (hazard ratio [HR]
0.61 and 0.73, respectively) [22]. Here we report a NAPOLI-1 post-hoc
analysis to further explore the benefits of nal-IRI + 5-FU/LV in older pa-
tients, according to age stratifications of b65/≥65, b70/≥70, and
b 75/≥75 years.
2. Methods
2.1. NAPOLI-1 Trial Design and Patients
NAPOLI-1 was an international, open-label, randomized, phase 3
trial, which has been previously described [22]. Briefly, trial participants
were adults aged ≥eighteen years (no upper age limit) with confirmed
metastatic pancreatic ductal adenocarcinoma and distant metastatic
disease who exhibited disease progression after prior gemcitabine-
containing therapy (neoadjuvant, adjuvant, locally advanced, or meta-
static setting). Patients had adequate haematological, hepatic, and
renal function, and Karnofsky performance status ≥70.
The trial was conducted in accordance with the Declaration of Hel-
sinki, the International Conference on Harmonization Guidance on
Good Clinical Practice, and the requirements of the US Food and Drug
Administration and local regulatory authorities regarding the conduct
of human clinical trials. Patients provided written informed consent,
and the trial was registered with ClinicalTrials. Gov (NCT01494506).
The study protocol was approved by institutional review boards of
both the study sponsor and of each participating study centre.
Patients were randomized to nal-IRI monotherapy, nal-IRI + 5-
FU/LV (following a protocol amendment), or a 5-FU/LV control [22].
nal-IRI monotherapy was given at 120 mg/m2 (expressed as irinotecan
hydrochloride trihydrate salt, equivalent to 100 mg/m2 expressed as
irinotecan free base) every three weeks, the combination arm com-
prised nal-IRI 80 mg/m2 (expressed as irinotecan hydrochloride
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opulation and age subgroups in the current analysis. Patients had metastatic pancreatic






















































429T. Macarulla et al. / Journal of Geriatric Oncology 10 (2019) 427–435base), 5-FU 2, 400 mg/m2, and LV 400 mg/m2 every two weeks, and the
control included 5-FU 2000 mg/m2 and LV 200 mg/m2 once weekly for
the first four weeks of a six-week cycle. Dose modifications were per-
mitted in order to help manage toxicities. Modifications included dose
delay (≤3 weeks) to allow recovery from toxicity, and dose reduction































































































































































































































































































































Age stratifications were applied with cut-offs at 65 years (b/
≥65 years), 70 years (b/≥70 years) and 75 years (b/≥75 years), based
on age at screening visit. The impact of age on outcomes, irrespective
of treatment allocation, was explored in the overall NAPOLI-1 intention
to treat (ITT) population (all patients randomized to any treatment
arm). Median OS and PFS were estimated for each age subgroup using
Kaplan-Meier analysis. HRs and corresponding 95% confidence intervals
(CI) were estimated for each pair of age subgroups (b65 versus
≥65 years; b70 versus ≥70 years; b75 versus ≥75 years) using unstrati-
fied Cox proportional hazards regression.
Efficacy of nal-IRI + 5-FU/LV, based onmedian OS, PFS, objective re-
sponse rate (ORR), and time to treatment failure (TTF), was analysed in
the subset of patients who were randomized to the combination and
control arms after addition of the combination arm (protocol version
2). This post-hoc analysis was not powered for formal assessment of
treatment differences; however, exploratory pairwise comparisons
were performed between study treatments within each age subgroup
by unstratified log-rank test. Additional efficacy analyses includedmea-
sures of tumour response per Response Evaluation Criteria in Solid Tu-
mours (RECIST) version 1.1, and changes in the biomarker
carbohydrate antigen 19-9 (CA19-9); response defined as ≥50% reduc-



















































































































































Safety and treatment exposure were evaluated within age sub-
groups in the combination arm only. Adverse events (AEs) were graded
according to the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE), version 4.0 in patients who re-
ceived ≥one dose (including a partial dose) of study treatment; haema-
tological parameters were assessed based on laboratory evaluations.
Shifts from baseline to end of treatment or highest post-dose CTCAE





















































































































































































































































































































































































3.1. Patient Characteristics and Disposition
A total of 417 patientswere enrolled and randomized in theNAPOLI-
1 trial (ITT population): 117 in the nal-IRI + 5-FU/LV arm, 149 in the
5-FU/LV control arm (119 were enrolled following the protocol amend-
ment and were included in treatment comparisons versus nal-IRI +
5-FU/LV), and 151 in the nal-IRImonotherapy arm (Fig. 1). In the overall
study population, themedian agewas 63.0 years (range 31–87) and the
mean age was 62.8 years. Almost half of the patient population (46%; n
=192)were aged ≥65 years, 25% (n=110)were ≥ 70 years, and 10% (n
= 43) were ≥ 75 years. In the efficacy analysis population (patients re-
cruited to the combination and control arms following protocol
amendment; n = 236) patient demographics and baseline charac-
teristics were generally similar between treatment arms overall
and within age subgroups (Table 1). The ≥75 years efficacy popula-
tion subgroup comprised only 20 patients (fourteen combination
and six control). Therefore, although results are presented along-
side those for the other age subgroups for completeness, the
small sample size limits interpretation of results for this age group.
Median,
mo (95% CI)
<65 yr 5.0 (4.4,6.0)
≥65 yr 4.8 (4.2,5.4)
HR: 0.88 (0.70,1.10),
P=0.262
<70 yr 4.9 (4.6,5.6)
≥70 yr 4.4 (4.0,5.9)
HR: 0.89 (0.70,1.14),
P=0.374
<75 yr 4.9 (4.5,5.4)





<65 yr 2.0 (1.5,2.7)
≥65 yr 2.7 (2.2,2.8)
HR: 0.95 (0.76,1.18),
P=0.627
<70 yr 2.4 (1.6,2.8)
≥70 yr 2.6 (1.6,2.9)
HR: 0.88 (0.69,1.11),
P=0.274
<75 yr 2.4 (1.7,2.7)



























































































































































Fig. 2. Overall survival (A) and progression-free survival (B) in the whole ITT population of the NAPOLI-1 trial split according to age subgroups. Patients had metastatic pancreatic
adenocarcinoma and had previously progressed on gemcitabine-based treatment.
430 T. Macarulla et al. / Journal of Geriatric Oncology 10 (2019) 427–4353.2. Impact of Age on OS and PFS in the Overall NAPOLI-1 Population
Risk of mortality and disease progression were similar in older and
younger age subgroups (Fig. 2). Median OS (Fig. 2a) was 5.0 months
in the b65 years subgroup (n = 225) versus 4.8 months in the
≥65 years subgroup (n = 192; HR 0.88 [95% CI: 0.70–1.10]; P = .262),
4.9 versus 4.4 months in b70/≥70 years subgroups (n = 307/110; HR
0.89 [0.70–1.14]; P = .374), and 4.9 versus 4.8 months in b75/
≥75 years subgroups (n = 374/43; HR 1.04 [0.73–1.49]; P = .817).In the overall population, median PFS (Fig. 2b) was 2.0 versus
2.7 months in the b65/≥65 years subgroups (HR 0.95 [0.76–1.18]; P =
.627), 2.4 versus 2.6 months in the b70/≥70 years subgroups (HR 0.88
[0.69–1.11]; P = .274), and 2.4 versus 2.8 months in the b75/
≥75 years subgroups (HR 0.98 [0.70–1.37]; P = .887).
3.3. Treatment Efficacy within Age Subgroups in the ITT Population
Consistent with findings in the overall ITT population [22], median
OS was longer with nal-IRI + 5-FU/LV compared with 5-FU/LV alone
Table 2
Efficacy of nal-IRI + 5-FU/LV combination therapy compared with control (5-FU/LV only) by age subgroup.






























Median 6.1 4.2 8.9 4.2 5.2 4.3 7.1 3.8 4.7 5.8 6.2 4.2 5.4 4.7
95% CI 4.8–8.9 3.3–5.3 5.3–10.5 3.2–6.1 4.2–6.4 2.7–6.1 5.3–9.3 3.1–5.3 3.6–6.7 2.8–7.0 4.9–8.9 3.2–5.3 3.3–10.2 2.2–NR
HR (95% CI) 0.67 (0.49–0.92) 0.62 (0.40–0.96) 0.69 (0.43–1.11) 0.63 (0.43–0.92) 0.79 (0.43–1.43) 0.66 (0.47–0.91) 0.75 (0.26–2.22)
p valuec 0.012 0.030 0.121 0.014 0.437 0.012 0.608
PFS (months),
Median 3.1 1.5 4.0 1.4 3.1 1.5 3.0 1.4 3.1 2.4 3.1 1.4 3.4 3.0
(95% CI) 2.7–4.2 1.4–1.8 1.5–5.6 1.3–1.9 2.7–4.2 1.4–2.6 2.4–4.3 1.4–1.6 1.5–4.2 1.4–3.0 2.4–4.2 1.4–1.7 1.2–6.1 1.3–5.6
HR (95% CI) 0.56 (0.41–0.75) 0.52 (0.35–0.78) 0.55 (0.35–0.88) 0.53 (0.37–0.75) 0.62 (0.34–1.11) 0.53 (0.38–0.73) 0.70 (0.23–2.09)
p valuec b 0.001 0.001 0.012 b 0.001 0.109 b 0.001 0.508
TTF (months),
Median 2.3 1.4 2.0 1.3 2.3 1.4 2.3 1.3 1.9 1.5 2.1 1.4 2.7 2.7
(95% CI) 1.6–2.8 1.3–1.4 1.5–4.2 1.2–1.4 1.4–2.8 1.3–1.6 1.6–2.9 1.2–1.4 1.4–2.9 1.3–2.6 1.6–2.8 1.3–1.4 1.2–3.4 1.3–5.6
HR (95% CI) 0.60 (0.45–0.78) 0.55 (0.38–0.79) 0.68 (0.45–1.03) 0.56 (0.41–0.77) 0.73 (0.43–1.26) 0.57 (0.43–0.76) 0.84 (0.31–2.28)
p valuec b 0.001 0.001 0.073 b 0.001 0.266 b 0.001 0.730
ORRa (%) 16 1 13 1 20 0 15 1 19 0 16 1 21 0
p value‡ b0.001 0.011 0.002 b0.001 0.027 b0.001 0.521
CA19-9 response
rateb
28/97 7/81 18/51 5/52 10/46 2/29 22/69 5/63 6/28 2/18 25/84 6/76 3/13 1/5
n/N (%) (29) (9) (35) (10) (22) (7) (32) (8) (21) (11) (30) (8) (23) (20)
p valued b0.001 0.002 0.113 b0.001 0.453 b0.001 1.000
Descriptive p values b.05 are highlighted in bold text.
CI, confidence interval; Comb, combination (nal-IRI+ 5-FU/LV); Ctrl, control (5-FU/LV); HR, hazard ratio; ITT, intent-to-treat efficacy analysis population (all patients randomized to com-
bination or control arms on protocol version 2); KPS, Karnofsky Performance Status; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TTF,
time to treatment failure.
a Breakdown of tumour responses is shown in Supplementary Table 1
b Response defined as ≥50% reduction in baseline CA19-9 levels, in patients with baseline levels N0.03 U/μl, and at least one post baseline CA19-9 measurement.
c Unstratified HR and log-rank P-value.
d Two-sided p values from pairwise Fisher's exact test.
431T. Macarulla et al. / Journal of Geriatric Oncology 10 (2019) 427–435in most age subgroups, with comparable magnitudes of mortality-risk
reduction (HRs ranging from 0.62 to 0.79, compared with 0.67 in the
overall ITT population) (Table 2; Fig. 3).
Of note, patients receiving nal IRI + 5-FU/LV who were b 65 years
(n = 63) had a median OS of 8.9 months and those ≥65 years
(n = 54) had a median OS of 5.2 months (HR 0.62 [0.39–0.99]; P
= .043). In comparison, patients in the 5-FU/LV control arm
b65 years (n = 77) had a 4.2-month median OS, and those
≥65 years (n = 42) had a 4.3-month median OS (HR 0.76
[0.49–1.19]; P = .230).
Median PFS and TTF were longer with nal-IRI + 5-FU/LV than with
5-FU/LV treatment across all age subgroups, with the exception of TTF
in the small ≥75 years subgroup (Table 2). Exploratory treatment com-
parisons between nal-IRI+ 5-FU/LV and 5-FU/LV alone showed statisti-
cally significant treatment benefits with nal-IRI + 5-FU/LV for OS, PFS
and TTF in the younger age subgroups (b65, b70, and b 75 years),
which had relatively large sample sizes. In older-age subgroups with
smaller populations, HRs favoured combination treatment but did not
reach statistical significance, except for PFS in patients ≥65 years
(Table 2).
The percentage of patients achieving ORR was considerably
higher in the combination therapy arm than the control arm in all
age groups (Table 2), as in the overall ITT population [22]. The treat-
ment difference reached statistical significance in all age subgroups
except the small ≥75 years group. A trend towards numerically
higher ORR was observed with nal-IRI + 5-FU/LV in the older sub-
groups (19–21%) versus the younger subgroups (13–16%) (Table 2;
breakdown of tumour response data in Supplementary Table 1). A
CA19–9 response was consistently achieved by a higher proportion
of patients receiving nal-IRI + 5-FU/LV (21–35% across age sub-
groups) compared with 5-FU/LV alone (7–11% in all subgroups ex-
cept ≥75 years, in which 20% of patients had a CA19-9 response)
(Table 2).3.4. Safety and Tolerability
The safety profile for nal-IRI + 5-FU/LV was similar across patient
subgroups, although the overall incidence of drug-related grade ≥ 3
AEs in the combination therapy arm was numerically lower in the
≥65 and ≥ 70 years groups (45–48%) than in the b65 and b 70 years
groups (57–59%). In the ≥75 age group the proportion of patients
with grade ≥ 3 AEs was similar to that in the b75 subgroup (57%
and 53%, respectively) (Table 3). The most common grade 3–4 non-
haematological AEs were late-onset diarrhoea (onset N24 h after
starting nal-IRI; no grade 3–4 early onset diarrhoea was reported),
fatigue, and vomiting (Table 3). However, fewer older (0–7%) than
younger (13–14%) patients reported vomiting, and nausea was
more common than vomiting in patients aged ≥65 years. Asthenia
was also less common in older (0–4%) versus younger (9–11%) age
subgroups, as was alopecia (6–7% versus 15–19%) and febrile neutro-
penia (3% in patients aged b65 years versus 0% in those above)
(Table 3).
A trend for a lower rate of grade 3–4 decreased neutrophil countwas
observed in older (10–15%) versus younger (21–25%) patients
(Table 3). Other haematological AEs occurred in similar proportions of
older and younger patients: 3–7% of patients across all age subgroups
had grade 3–4 decreased haemoglobin and only two patients, both
aged b65, had grade 3–4 decreased platelet count.
3.5. Treatment Exposure, Dose Modifications, and Dose Intensity
The average duration of treatment exposure in the combination
arm was 15 weeks overall. Treatment duration tended to be slightly
shorter in older patients (13 versus 17 weeks for ≥65/b65 years; 13
versus 16 weeks for ≥70/b70 years), consistent with somewhat
higher rates of discontinuation due to treatment-emergent AEs


















































































Fig. 3.Overall survival in patients aged b65 (A) or ≥ 65 (B) in the NAPOLI-1 trial receiving nal-IRI + 5-FU/LV versus 5-FU/LV only. Patients hadmetastatic pancreatic adenocarcinoma and
had previously progressed on gemcitabine-based treatment.
432 T. Macarulla et al. / Journal of Geriatric Oncology 10 (2019) 427–435compared with 8–9% in b65 and b 70 age groups). When the highest
age split (≥75/b75) was applied, treatment duration (14–15 weeks)
and discontinuation rates (11–14%) were more similar, suggesting
that the 70–74 age group (n = 17) contributed to higher discontin-
uation rates and shorter treatment durations in their respective sub-
groups. The proportion of patients requiring dose modifications
(dose delay or reduction) due to TEAEs were broadly similar across
most age subgroups, but were numerically higher in the small
≥75 years subgroup: 86% (12 of 14 patients) required dose modifica-
tion comparedwith 69% (71 of 103 patients) aged b75 years. Dose re-
ductions were required by 6 patients (43%) in the ≥75 years
subgroup and 33 patients (32%) aged b75 years (Table 4). Similarly,
average relative dose intensity was slightly lower in the ≥75 years
age group (76% for nal-IRI and 78% for 5-FU/LV in the combinationarm) compared with other subgroups (82–85% for both treatment
components) (Table 4).
4. Discussion
We sought to explore the impact of age on outcomes in the NAPOLI-
1 trial, and to evaluate the potential for nal-IRI+ 5-FU/LV to improve ef-
ficacy in older patients withmetastatic pancreatic adenocarcinoma that
had progressed on prior gemcitabine-based therapy.MedianOS and PFS
were similar across all age subgroups when treatment arms were com-
bined, indicating that increasing age is not prognostic of mortality or
disease progression in this population and that treatment should not
be withheld due to age alone for eligible and sufficiently fit patients.
Our results also suggest that the clinical benefit of nal-IRI + 5-FU/LV
Table 3















Drug related AE of CTCAE grade ≥ 3 (%) 54 59 48 57 45 53 57
Grade 3–4 non-haematological AEs in N5% of patients (%)
Diarrhoea (late onseta) 13 14 11 13 13 13 14
Vomiting 11 14 7 14 3 13 0
Nausea 8 5 11 8 6 8 7
Fatigue 14 13 15 14 13 14 14
Asthenia 8 11 4 9 3 9 0
Abdominal pain 7 8 6 8 3 7 7
AEs of special interest (%)
Alopecia (grade 1–2) 14 19 7 16 6 15 7
Febrile neutropenia (grade 3–4) 2 3 0 2 0 2 0
Grade 3–4 haematological AEs based on laboratory values (% evaluable patients)










































AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events, version 4.0.
a N24 h after starting nal-IRI (no grade 3/4 early onset diarrhoea [≤24 h after starting nal-IRI] reported).
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tained across age subgroups: HRs for nal-IRI + 5-FU/LV versus 5-FU/
LV alone were consistently less than one for multiple outcomes across
all ages.
The side-effect profile of nal-IRI + 5-FU/LV in older patients in the
NAPOLI-1 trial was manageable and predictable. No additional adverse
events were associated with combination treatment in older versus
younger patients and the incidence of neutropenia and some of the
more common treatment-related grade 3–4 AEs, including vomiting
and asthenia, was lower in older patients. This may in part be explained
by the slightly higher rate of discontinuation due to TEAEs in older pa-
tient subgroups (≥65 years and ≥ 70 years) treated with nal-IRI + 5-
FU/LV compared with younger patients, which led to a numerically
shorter average treatment duration but similar dose intensities. In addi-
tion, dose modifications (delays or reductions) were reported in a
higher percentage of patients ≥75 years versus younger patients and it
is possible that this also had an impact on the incidence of adverse
events in this subgroup. A recent post-hoc analysis suggested that
dose modification had no significant impact on survival outcomes in
the overall NAPOLI-1 population [23]. In the current subgroup analysis,
older age groups had numerically lower median OS versus younger pa-
tients but no trend in median PFS was observed.
The lack of additional toxicities in older patients is encouraging and
in contrast to other regimens. For example, a retrospective study of
FOLFIRINOX (5-FU, LV, irinotecan and oxaliplatin) in older patients
(70–79 years) in five centres in France found that, while efficacy was
similar to that reported for younger patients in the phase II/IIITable 4





Patients with TEAE leading to any dose modification (%) 71 73
Patients with TEAEs leading to dose reduction (%) 33 37
Patients with TEAEs leading to dose delay (%) 62 65
Patients with TEAEs leading to treatment discontinuation (%) 11 8
Mean relative dose intensity (%)
nal-IRI 83 82
5-FU/LV 84 83
Mean duration of treatment exposure (weeks) 15 17
5-FU/LV, 5-fluorouracil/leucovorin; nal-IRI, liposomal irinotecan; TEAE, treatment emergent adPRODIGE 4/ACCORD 11 trial (which excluded patients aged N75 years)
[10], there was an increased incidence of grade 3 neurotoxicity in
older patients [24].
nal-IRI represents an improved formulation of irinotecan in various
respects. Firstly, nal-IRI is a stable liposomal formulation of irinotecan,
which exhibits extended systemic circulation of irinotecan compared
with non-liposomal irinotecan; at all time points, 95% of the irinotecan
in plasma is contained in the liposome [25]. Furthermore, the liposomal
formulation has been shown to increase and prolong intra-tumoural
levels of irinotecan and its active metabolite SN-38 [26,27], with in-
creased antitumor activity in vitro at a five-fold lower dose than non-
liposomal irinotecan [26].
Our post-hoc analysis with multiple age cut-offs permitted explora-
tion of outcomes in older patients with greater sensitivity than the pre-
specified subgroup analysis of a single 65-years cut-off [22] as it re-
vealed variation within the relatively large ≥65 years group [9]. Indeed,
some patterns (treatment duration, discontinuation rates, and overall
incidence of AEs) observed when the age split was applied at 65 and
70 years, were not apparent with a 75-years split. This suggests a possi-
ble transition in the 70–74 age group, although this is difficult to evalu-
ate due to the relatively small sample size of this group in the NAPOLI-1
population. Additionally, limited interpretations can be made with re-
sults using the b75/≥75-years split, due to the very small size of the
≥75 years subgroup. The use of multiple age cut-offs also highlights
that there is no universally accepted definition of ‘elderly’ [28], and in-
creased life expectancy and improved therapies have led to shifting per-
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A retrospective population-based study in the Netherlands found that
patients receiving no tumour-targeted treatment were significantly
older than patients who did receive tumour targeted treatment
(74 years versus 66 years; P b .001); furthermore 2.3% of patients with
pancreatic cancer received no tumour-targeted treatment due to ‘old
age’, despite 37% of these patients having a stage 1 tumour [12]. Addi-
tionally, these patients were less often discussed in a multidisciplinary
team consultation. Despite this apparent lack of enthusiasm for treat-
ment of older patients, a recent prospective French study investigating
geriatric prognostic factors in the pancreatic adenocarcinoma setting
found that Lawton's Instrumental Activities of Daily Living impairment,
Cumulative Index Rating Scale-Geriatric ≥2 and weight loss N10%, but
not age, were prognostic factors for survival in patients N70 years of
age. The investigators concluded that almost 90% of their older patient
population could benefit from the same treatment as younger patients
[29]. Further research on geriatric assessments and the real-world use
of such assessments is warranted.
The NAPOLI-1 trial population was fairly typical of clinical trials in
this field in terms of age characteristics [30–32]. It included patients
aged up to 87 years, with 46%, 25%, and 10% of patients aged over 65,
70, and 75 years, respectively. This compares with reported age distri-
bution of 64–67% aged ≥65, 50% aged ≥70, and 36–39% aged ≥75 in the
general pancreatic cancer population [1,2,9]. NAPOLI-1 was not de-
signed prospectively as a study of older patients, and no geriatric evalu-
ation tests were conducted to describe the older portion of the trial
population. Therefore, one limitation of this analysis is that, despite
lack of an upper age limit in the enrolment criteria for NAPOLI-1, the
trial population contained a lower proportion of older patients than
the general metastatic pancreatic adenocarcinoma population. It is not
clear to what extent the older patients in this analysis reflect the health
or performance status of those in clinical practice. Clinical trial popula-
tions are highly selective, and frailer patients may have been excluded
on the basis of criteria relating to performance status, comorbidities,
or hepatic or renal function, thereby being under-represented. An anal-
ysis of the Netherlands Cancer Registry reported worse outcomes in
older patients receiving chemotherapy in the ‘real-life’ setting than
those reported in clinical trials [9].
Another limitation of this analysis is that it was not powered to de-
tect statistically significant treatment effects within age subgroups. For
most outcomes, statistical significance was reached in the larger, youn-
ger age groups but not the smaller, older age groups. However, given the
consistent trends in the magnitude and direction of treatment effect,
and differences in subgroup sizes, the lack of statistical significance in
older age groups may reflect smaller group sizes rather than reduced
treatment effect of nal-IRI + 5-FU/LV in older patients.
Nearly half of the NAPOLI-1 populationwas aged ≥65 years, and out-
comes in the older patient subgroups were consistent with those in the
wider trial population. Therefore, despite some limitations, this analysis
provides valuable insights into treatment response in older patients
withmetastatic pancreatic adenocarcinoma. In the context of a reported
4.6-monthmedian OS from diagnosis in patients with pancreatic cancer
treated in the real-world European setting [33], it is clear that appropri-
ate treatment can improve individual outcomes, irrespective of patient
age.
In conclusion, this analysis indicates that older patients with meta-
static pancreatic adenocarcinoma who have previously progressed on
gemcitabine-based treatment can benefit from second-line treatment.
Agewas not a prognostic factor for decreased survival in this study pop-
ulation and our observations of clinical benefit with nal-IRI + 5-FU/LV
were consistent with those observed in the wider trial population.
These results support the use of nal-IRI + 5-FU/LV in older patients
with metastatic pancreatic adenocarcinoma following gemcitabine-
based therapy.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jgo.2019.02.011.Author Contributions
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